Across TCGA pan-cancer cohorts, KRT83 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated KRT83 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher KRT83 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRT83 expression acts as an unfavorable survival marker.
STAD and LGG are the cancer types where KRT83 Mutation most reproducibly stratifies survival.